

Table S1 Baseline characteristics of patients in the single-center cohort

Parameters	Single-center cohort (N=1049)
Age (years), mean (SD)	68.0 (10.9)
Sex, n (%)	
Male/female	873 (83.2)/176 (16.8)
Etiology, n (%)	
Alcohol/virus/MASLD	340 (32.4)/354 (33.8)/199 (18.9)/
Alcohol + virus/MASLD + virus/other	66 (6.3)/0 (0)/90 (8.6)
ECOG PS, n (%)	
0/1/2/3	560 (53.4)/241 (23)/203 (19.3)/45 (4.3)
Cirrhosis, n (%)	929 (88.6)
EV [†] , n (%)	355 (38.2)
Child-Pugh grade, n (%)	
A/B/C	717 (68.4)/312 (29.7)/20 (1.9)
BCLC stage, n (%)	
A/B/C/D	469 (44.7)/185 (17.6)/274 (26.2)/121 (11.5)
MVI, n (%)	
Yes	281 (26.8)
Type, n (%)	
Type I/type II	20 (7.0)/137 (49.0)
Other	124 (44.0)
Extrahepatic metastasis, n (%)	53 (5.1)
Tumor burden Nodules, n (%)	
1/2/3/>3	522 (50.4)/147 (14.2)/52 (5.0)/314 (30.3)
Infiltrative mass, n (%)	346 (33.0)
Maximal tumor diameter mm, mean (SD)	53.1 (42.7)
Laboratory results	
Hemoglobin g/dL, mean (SD)	-
Platelets count (×1000/μL), mean (SD)	164.8 (97.1)
Neutrophil count (×1000/μL), mean (SD)	-
Lymphocyte count (×1000/μL), mean (SD)	1412 (1266)
C-reactive protein mg/L, mean (SD)	20.0 (32.8)
AST IU/L, mean (SD)	85.2 (108.1)
ALT IU/L, mean (SD)	-
GGT IU/L, mean (SD)	-
ALP IU/L, mean (SD)	153.0 (133.5)
Bilirubin μmol/L, mean (SD)	35.0 (135.7)
Albumin g/L, mean (SD)	34.6 (6.9)
Creatinine μmol/L, mean (SD)	-
Prothrombin time %, mean (SD)	77.0 (17.5)
AFP ng/mL, mean (SD)	6041 (43 896)
Albumin-Bilirubin grade, n (%)	
1/2/3	243 (24.9)/562 (57.5)/172 (17.6)
Follow-up duration (months), median (Q1–Q3)	17.0 (5.6–40.0)

[†], esophageal varices in patients with cirrhosis; Child-Pugh grade calculated for all patients; single-center cohort (tumor burden nodules): data for 1,035 patients; Albumin-Bilirubin grade: data from 977 patients. AFP, alfa-fetoprotein; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer; ECOG PS, Eastern Cooperative Oncology Group Performance Status; EV, esophageal varices; GGT, γ-glutamyl transpeptidase; MVI, macrovascular invasion; MASLD, metabolic dysfunction-associated steatotic liver disease; SD, standard deviation.

Table S2 Median overall survival of patients from the single-center and SIRT cohorts with BCLC stage C HCC with unilateral intrahepatic portal vein invasion according to treatment modality

BCLC stage C HCC with unilateral portal tumor vein thrombosis	OS (months), median (Q1–Q3)	Hazard ratio (95% CI)	P
Treatments			
Surgical resection (n=10)	31.7 (10.2–infinite)	0.83 (0.32–2.11)	0.6887
TACE (n=44)	11.1 (6.7–16.7)	2.03 (1.09–3.79)	0.0266
TKI (n=41)	8.0 (4.3–11.5)	3.25 (1.72–6.11)	0.0003
Atezolizumab + bevacizumab (n=9)	Not defined	0.23 (0.03–1.79)	0.1621
SIRT (n=26)	16.0 (8.0–infinite)	Ref	Ref
P(log-rank)	<0.0001	-	-

BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma; OS, overall survival; SIRT, selective internal radiation therapy; TACE, transarterial chemoembolization; TKI, tyrosine kinase inhibitor.